Bayer Trades One Risk for Another: Glyphosate Court Victory Paves Way for Trade War With China

Bayer files anti-dumping petition against Chinese glyphosate imports, risking farmer relations, while stock surges 104% but shows overbought signals; pharma faces IRA pressure.

The script could hardly be more dramatic. Five days after capping a decade-long legal nightmare, Bayer tore open a new front — this time aimed not at plaintiffs’ lawyers but at Beijing. The DAX-listed chemical giant filed an antidumping petition on June 30, 2026, demanding tariffs on Chinese glyphosate imports. The move marks a radical shift in strategy: having just contained its US litigation exposure, the company now risks alienating the American farmers who buy its herbicides.

The latest legal truce came when a US court pared a particularly painful verdict to $1.25 million. That small mercy sits atop more than $10 billion in cumulative litigation costs. But Bayer wasted no time capitalizing on the relief. Its newly formed US subsidiary, Ruveon LLC, headquartered in St. Louis, will bundle all American glyphosate operations — production, logistics, pricing — giving management a single vehicle to enforce trade protection. The petition, filed with the US Department of Commerce and the International Trade Commission, accuses Chinese producers of dumping cut-price generics on the market.

CEO Bill Anderson had previously warned he might shutter US production if cheap imports continued to squeeze margins. The tariff gambit is the logical endgame of that threat. Yet it pits Bayer against some of its biggest customers. The American Corn Growers Association and the National Soybean Association have already lobbied against the move, arguing that higher duties will inflate input costs for farmers already struggling with thin margins.

For all the strategic bustle, the stock market has looked the other way. Bayer shares closed at €53.28 on Friday, barely a whisker below the 52-week high touched the same day. The price has surged 104.33% over twelve months and 40.12% since the start of 2026. The rally has been so relentless that the stock now towers 43.56% above its 200-day moving average.

Technicians are sounding alarms that the chart is stretched to breaking point. The Relative Strength Index sits at 85.3, deep in overbought territory. Annualised volatility clocks in at 63.23%, reflecting the hair-trigger sensitivity of the shares to any news on the glyphosate front. A healthy pullback would be textbook — but momentum traders have ignored the warning so far.

Beyond the courtroom and the trade office, the pharma division still faces real pressure. The US Inflation Reduction Act is squeezing drug prices, and Bayer’s blockbuster blood thinner Xarelto is among the first ten medicines subject to government-negotiated ceilings. Those caps kicked in at the start of 2026, compressing margins in the world’s most lucrative drug market. While AI is accelerating early-stage R&D, the near-term earnings outlook remains clouded. Some analysts are eyeing European specialty drugs as a potential offset.

The next genuine catalyst is weeks away: a mandatory quiet period begins in mid-July and runs until second-quarter earnings on August 4. That vacuum of hard data leaves the narrative in the hands of trade-watch agencies and the tape. If the Commerce Department approves the tariff petition, farmers will foot the bill. If it rejects it, Bayer’s US glyphosate business stays vulnerable. Either way, the market is betting that one risk neatly replaces another — a bet that history suggests rarely pays off for long.